生物靶向药物在哮喘气道黏液栓治疗中的价值

Value of biotargeted drugs in airway mucus therapy of asthma

气道黏液栓是哮喘中常见的一种表型,通过引起气流阻塞加重而使哮喘急性发作风险增高。鉴于其在哮喘中的重要作用,针对气道黏液栓的治疗或将成为控制哮喘进展、预防或解除致死性哮喘发作的策略。既往研究表明,嗜酸粒细胞、T2型炎症等与黏液栓的形成有关,针对上述通路的生物靶向药物可能在治疗气道黏液栓方面发挥疗效。

Airway mucus plug is a common phenotype in asthma that increases the risk of acute asthma attacks by causing aggravation of airflow obstruction.Given its important role in asthma,treatment targeting airway mucus plugs may be a strategy to control asthma progression and prevent fatal asthma exacerbations.Previous studies have shown that acidosophils and T2 type inflammation are related with the formation of mucus plugs,and biotargeted drugs targeting the above pathways may be effective in the treatment of airway mucus plugs.